DUBLIN, Aug. 2, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that it has appointed Laure Park as Senior Vice President, Investor Relations and Corporate Affairs, effective immediately.
"I am excited to welcome Laure to lead Endo's Investor Relations and Corporate Affairs team. Given Laure's strong financial acumen, business leadership experience and communications background, she is well qualified for her new position, where she will serve as a member of Endo's executive leadership team," said Paul Campanelli, President and Chief Executive Officer of Endo. "I'm confident Laure will make significant contributions to Endo and I look forward to working with her."
Prior to joining Endo, Ms. Park spent 23 years at Quest Diagnostics where she held a multitude of leadership roles in different functional areas, including finance, investor relations and communications. Most recently, she served as Quest's Vice President, Customer Experience where she was responsible for building a customer-focused culture and representing the customer in the design and delivery of the customer experience. Prior to that, she was Vice President, Communications & Investor Relations, responsible for leading investor relations and integrating it with the company's internal and external communications functions. Laure started her career in public accounting with Deloitte & Touche in 1987, before joining Quest's finance organization in 1995. Ms. Park graduated from the University of North Dakota with bachelors degrees in accounting and communications. She's a member of the Healthcare Businesswomen's Association (HBA) and has served as a director of the East Region of the American Cancer Society and the New Jersey Chapter of the Leukemia and Lymphoma Society.
"I am excited to serve Endo, our employees, shareholders and customers in my new role," said Ms. Park. "I look forward to leading investor relations and communications, especially at this important time."
About Endo International plc
Endo International plc (NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.
Cautionary Note Regarding Forward-Looking Statements
Certain information in this press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation, including, but not limited to, statements by Mr. Campanelli and Ms. Park. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and in Canada on the System for Electronic Data Analysis and Retrieval and as otherwise enumerated herein or therein, could individually or in the aggregate affect Endo's future financial results and could cause Endo's actual results to differ materially from those expressed in the forward-looking statements or from historical results. The forward-looking statements in this press release are qualified by these risk factors. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.
SOURCE Endo International plc